Evidence map›Paper›PMID 39621212›Full record

ArticleEJNMMI radiopharmacy and chemistry2024

An ACE2 PET imaging agent derived from

Pan Zhou, Kai Ning, Shuai Xue, Qingqing Li, Danni Li, Haijun Yang, Zeying Liang, Rou Li, Jian Yang, Xiao Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pan Zhou *Department of Nuclear Medicine, Shanghai Changhai Hospital, Shanghai, 200433, China.
Kai Ning *Artery Pharmaceuticals, Shanghai, 201413, China.
Shuai XueShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China.
Qingqing LiArtery Pharmaceuticals, Shanghai, 201413, China.
Danni LiDepartment of Nuclear Medicine, Shanghai Changhai Hospital, Shanghai, 200433, China.
Haijun YangSchool of Medicine, Shanghai University, Shanghai, 200444, China.
Zeying LiangSchool of Medicine, Shanghai University, Shanghai, 200444, China.
Rou LiDepartment of Nuclear Medicine, Shanghai Changhai Hospital, Shanghai, 200433, China.
Jian YangSchool of Medicine, Shanghai University, Shanghai, 200444, China. yj_scu@163.com.
Xiao LiDepartment of Nuclear Medicine, Shanghai Changhai Hospital, Shanghai, 200433, China. lixiao@sinap.ac.cn.
Lan ZhangShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China. zhanglan@sinap.ac.cn.

Funding

Construction Project of Shanghai Key Laboratory of Molecular Imaging 18DZ2260400Construction Project of Shanghai Key Laboratory of Molecular Imaging KFKT-2022-08Construction Project of Shanghai Key Laboratory of Molecular Imaging KFKT-2023-40National Natural Science Foundation of China 82402423
6 · The paper itself

Abstract

backgroundAngiotensin-converting enzyme-2 (ACE2) acts as a key regulatory molecule and important therapeutic target in the pathological remodeling of numerous organs and diseases. In this study, a rapid, simple, and efficient synthetic route with a catalytic,

resultsA novel

conclusion

Indexed as

18F/Cl exchangeACE2MLN−4760PET imaging agentPhase transfer catalysis

Identifiers

PMID39621212
PMCPMC11612064

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.